ODI Pharma AB reported earning results for the fourth quarter and full year ended June 30, 2021. For the quarter, the company reported Group's loss after financial items amounted to SEK 1,886,158 compared to SEK 1,229,862 a year ago. Loss per share amounted to SEK 0.12 compared to SEK 0.08 a year ago. For the full year, the company reported Group's loss after financial items amounted to SEK 3,967,324 compared to SEK 4,942,199 a year ago. Loss per share amounted to SEK 0.26 compared to SEK 0.36 a year ago.